openPR Logo
Press release

Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market, 2016 - 2022

Global Recurrent Glioblastoma Multiforme (GBM) Treatment

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure, nausea, headache, hemiparesis and memory loss are some of the common symptoms observed in the patients suffering from GBM. GBM is most commonly found in male with the age of 65 years and above.

Alcohol consumption and malaria are the possible risk factors for the development of GBM. In addition, neurofibromatosis, tuberous sclerosis, von-hippel-lindau disease, Li-fraumeni syndrome and turcot syndrome are some of the genetic disorders that are associated with increasing incidences of gliomas. Glioblastoma multiforme is a World Health Organization Grade IV tumor that represents 15 to 20% of all primary intracranial tumors.

Increasing habits of alcohol consumption, changing lifestyle and increasing incidence of seizure are some of the drivers for the growth of GBM market. GBM is generally treated by first surgically removing the tumor then treating with chemotherapy and radiation. While this treatment plan is the currently accepted standard of care, it does not effectively prevent tumor recurrence, which ultimately causes death in GBM patients. This factor is expected to be the prime restraint for the growth of recurrent glioblastoma multiforme market.

Recurrent Glioblastoma Multiforme (GBM) market is segmented on the basis of treatment, end user and geography.

Based on treatment, GBM market can be segmented as follows:
Oral Medications
Temozolomide
Radiosensitizers
Nitrosoureas Drugs
Radiation therapy
Chemotherapy

Based on end user, GBM market can be segmented as follows:
Hospitals
Clinics
Ambulatory surgical centers
Primary treatment involves surgery to achieve tumor debulking, followed by a multimodal regimen of radiotherapy and chemotherapy. Chemotherapy can be added to radiotherapy for patients with unfavorable low-grade glioma to improve progression free survival. The most frequently used chemotherapy regimens are a combination of procarbazine, lomustine and vincristine, or single-agent treatment with carmustine or lomustine. Temozolomide is recommended by NICE as an option for the treatment of newly diagnosed GBM. Concomitant and adjuvant chemotherapy with temozolomide given during and after radiotherapy improves survival. This drug used along with chemotherapy or radiotherapy has led to the growth of GBM treatment market to a great extent.

Request Brochure of this Report: http://www.persistencemarketresearch.com/samples/10112

Region wise, the global recurrent glioblastoma multiforme (GBM) market is classified into regions namely, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominates the global GBM market owing to rising awareness, population aging, changing lifestyle and increasing healthcare awareness accentuates the growth of GBM market in these regions. In addition, Asia-Pacific region is expected to be an emerging market due to increasing demand for better healthcare facilities.

Request to view TOC: http://www.persistencemarketresearch.com/toc/10112

Some of the companies competing in recurrent glioblastoma multiforme (GBM) treatment market are Astrazeneca, F. Hoffman-La Roche, Ltd., GlaxoSmithKline plc., Merck & Co., Inc., Pfizer, Inc., AngioChem, Inc. Vascular Biogeneics and others.

About Us:
Persistence Market Research (PMR) is an innovative provider of market research reports and consulting services. The three PMR pillars of strength that have helped us win clients for years are: Quality Research, Quick Research, and In-depth Research.

PMR’s team of seasoned analysts and consultants are experts in their domain. At PMR, we process complex, exhaustive primary and secondary research data into valuable insight. We Understand that each client has a unique problem statement, and address it with our strengths.

Contact:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: +1 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market, 2016 - 2022 here

News-ID: 339939 • Views: 322

More Releases from Persistence Market Research Pvt. Ltd

Global HPMC Capsules Market is expected to reach a Valuation of US$ 554.5 Mn Ove …
HPMC capsules are strictly non-toxic and qualify to be Kosher and Halal-certified, which is why their popularity has grown in several parts of the world. Moreover, these capsules can significantly boost the body metabolism by improving absorption and digestion of protein, fat and carbohydrates. HPMC capsules find their application in the preparation of non-animal based medicines and cosmetics & nutraceuticals products. Persistence Market Research (PMR) recently conducted a study
Vacuum Tissue Processor Technology Most Favored in the Global Tissue Processing …
Persistence Market Research has come up with a fact based analytical research study describing various aspects of the tissue processing systems market across the globe. The analysis on tissue processing systems has been systematically drafted in a new research publication titled “Tissue Processing Systems Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)”. This comprehensive research report focuses on various developments, trends, restraints, opportunities, drivers and challenges impacting revenue growth of
Endodontics Market Is Projected To Grow At A Moderate CAGR During The Period Of …
Endodontics is associated with the dentistry segment. It involves several therapies to protect the human teeth from infections and injuries caused to the dental pulp. Generally, it is concerned with morphology, pathology as well as physiology of dental pulp and the periradicular tissues. Endodontics is important during carrying out root canal procedure in order to reduce the inflammation and to end infection. Modernization has touched the field of endodontics as
Global Home Infusion Therapy Devices Market Driven by Growing Incidence of Pain, …
According to the latest market report published by Persistence Market Research titled ‘Home Infusion Therapy Devices Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025),’ the global Home Infusion Therapy Devices market is expected to expand at a CAGR of 6.8% during the forecast period 2017–2025. Persistence Market Research delivers key insights and presents a revised forecast of the global Home Infusion Therapy Devices market for an eight year period from

All 5 Releases


More Releases for GBM

Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. Request Sample Report: https://precisionbusinessinsights.com/request-sample?product_id=16248 The global glioblastoma multiforme treatment market is
Glioblastoma Multiforme Treatment (GBM) Market is exhibiting a positive CAGR of …
Keen players in the global glioblastoma multiforme (GBM) treatment market are striving to maintain their foothold via novel product offerings. These players are focusing hard on the development of newer biological drugs with fewer side effects, which are usually associated with the consumption of immunosuppressants and chemotherapeutic agents. Collaborations with diagnostic laboratories in order to raise awareness regarding treatment options for glioblastoma multiforme is another key growth strategy adopted by market
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016
Summary: ReportsWeb.com published “Glioblastoma Multiforme (GBM)” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Original Content: Publisher's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging
Glioblastoma Multiforme Treatment (GBM) Market Will Increase Strongly Through 20 …
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging